<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjustment of the dosage of the dexamethasone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLARITHROMYCIN" rxcui="21212">
<ATC code="J01FA09" />
<ATC code="A02BD04" />
<ATC code="A02BD05" />
<ATC code="A02BD06" />
<ATC code="A02BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="POSACONAZOLE" rxcui="282446">
<ATC code="J02AC0" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAZIQUANTEL" rxcui="8628">
<ATC code="P02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Separate the administration of the two medications by at least a week.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir by increase of its hepatic metaolism by the dexamethasone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>With the exception of dexamethasone administered in a single dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>171-DEXAMETHASONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
<ATC code="D07CB04" />
<ATC code="S01CA01" />
<ATC code="S02CA06" />
<ATC code="S03CA01" />
<ATC code="R01AD53" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
